A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Detailed PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of ...

A new injectable radioactive diagnostic agent for positron-emission tomography (PET) imaging for men with prostate cancer has been approved by the US Food and Drug Administration (FDA). PSMA PET has ...

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen ...

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation. Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis ...

Getty Images In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression. Positive results on PSMA PET/CT scans predict more ...